Drug Trial Radar · NCT07816198
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
354
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
AD-233ADrug
PO, Once daily(QD), 24 weeks
AD-233BDrug
PO, Once daily(QD), 24 weeks
AD-233CDrug
PO, Once daily(QD), 24 weeks
AD-233DDrug
PO, Once daily(QD), 24 weeks
AD-233A PlaceboDrug
PO, Once daily(QD), 24 weeks
AD-233B PlaceboDrug
PO, Once daily(QD), 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c(Hemoglobin a1c) from baseline at Week 24 after administration of IP(Investigator's Product)Time frame: Baseline, Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.